A man with prostate cancer is the first NHS patient in the UK to have an implant which reduces the side effects of radiotherapy by 70%.
In order to amount of Radiation, Prostate Gel spacer increases the space between rectum and prostate. Prostate cancer is the most common cancer in men, with more than 40,000 new cases diagnosed in England each year. If prostate cancer is diagnosed early then radio therapy is highly effective. This treatment will be available in twelve hospitals in the UK; high-energy X-rays are targeted at the prostate, killing cancer cells and preventing them from spreading. The radiation is not absorbed by the prostate that is close to healthy organs, resulting in side effects of bowel and bladder damage.
Alan Clarke, from Bristol, first had radiotherapy in 2011 but the cancer returned. He was selected as the first NHS patient to receive the spacer because he was considered to be more at risk of suffering with side effects from a second course of radiotherapy.
Prof Amit Bahl, consultant oncologist at the University Hospitals Bristol NHS Foundation Trust, said: “The space we have created means the rectum will not get the toxicity from the radiotherapy.”
Dr Sam Roberts, director of innovation and life sciences for NHS England, said: “In studies, its use has been shown to relatively reduce life-changing side effects, such as rectal pain, bleeding and diarrhea, by over 70%, meaning significant improvements in quality of life for those battling prostate cancer.”
Prostate Cancer: Symptoms
- One needs to run to toilet frequently.
- Has trouble to urinate.
- Has weak urine flow.
- Feels need to urinate more frequently.